FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.
People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.
The conversation discusses using topical spironolactone for hair loss, with the original poster already using oral and topical minoxidil, dutasteride, and latanoprost. Opinions differ on the effectiveness and safety of adding spironolactone, with some users suggesting alternative treatments like finasteride and vitamin supplements.
A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.
Hair loss treatments, specifically the use of Alfatradiol as an over-the-counter topical 5AR inhibitor that has been shown to be effective in stopping hair loss without side effects. Other treatments discussed include Minoxidil, finasteride and RU58841.
User 1: Female, 24, prescribed 2.5mg oral minoxidil and 100mg spironolactone, asks about others' experiences. User 2: Male, 32, took oral minoxidil for a year, saw better results at 3.75mg, experienced thicker eyebrows, longer eyelashes, and longer body hair.
Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.
The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.
The conversation is about the perceived risks of oral minoxidil compared to spironolactone for treating hair loss, with the original poster currently taking spironolactone due to concerns about oral minoxidil's safety.
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
Topical estradiol may help with hair loss but can have systemic effects, like reduced testosterone production. Using estrogen blockers can have negative side effects, such as joint pain and reduced sex drive.
Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.
Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.
A user started taking finasteride 1mg/day for hair loss but hasn't seen results yet. They also take vitamins and asked about adding minoxidil and the effectiveness of LLLT.
A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.
Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.
The user has tried various hair loss treatments, including topilutamide, alfatradiol, pyrilutamide, and topical spironolactone, but experienced headaches. They are inquiring about the availability and legality of clascoterone in Spain.
A new hair loss treatment, Pyrilutamide, has been released and is claimed to be a strong anti-androgen, potentially effective when used with finasteride. However, there are mixed opinions on its effectiveness and safety, with some users skeptical and others purchasing it.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
The user is using 1mg oral finasteride, 1.25mg oral minoxidil nightly, and ketoconazole shampoo weekly for hair loss, reporting no side effects. They self-prescribed after inconsistent use of topical minoxidil, using Lonitab from Intas pharmaceutical.
Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.
The user is treating alopecia areata with 1.25mg oral minoxidil daily and topical mometasone furoate, considering increasing the dose or adding finasteride, though finasteride is not typically used for this condition. A gluten-free diet is suggested, and alternatives like Olumiant are mentioned.
Using licorice to counteract the blood pressure-lowering effects of oral minoxidil. Concerns about licorice affecting potassium levels and minoxidil's effectiveness were raised.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.